Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma.
Chemotherapy
Esophageal squamous cell carcinoma
Immunotherapy
Prognosis
Radiotherapy
Treatment-related adverse events
Journal
Discover. Oncology
ISSN: 2730-6011
Titre abrégé: Discov Oncol
Pays: United States
ID NLM: 101775142
Informations de publication
Date de publication:
04 Sep 2023
04 Sep 2023
Historique:
received:
07
05
2023
accepted:
28
08
2023
medline:
4
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
This study was designed to investigate the efficacy and prognostic factors for immune checkpoint inhibitors (ICIs) combined with or without radio(chemo)therapy and to evaluate their toxicity in patients with locally advanced or recurrent/metastatic esophageal squamous cell carcinoma (LA/RM ESCC). In this study, 198 patients with locally advanced or recurrent/metastatic (LA/RM) ESCC who received ICIs combined with or without radiotherapy/chemotherapy in the Department of Radiotherapy of the Fourth Hospital of Hebei Medical University were retrospectively analyzed. Univariate and multivariate analyses were performed to determine the prognostic factors for overall survival (OS) and progression free survival (PFS). The factors affecting treatment response and the occurrences of treatment-related adverse events (trAEs) were analyzed. The median OS and PFS were 30.4 months (95% confidence interval [CI] 15.1-45.7 months) and 15.3 months (95% CI 12.8-17.8 months), respectively. Univariate and multivariate analysis showed that the number of ICI cycles, the intervention of radiotherapy and dysphagia were independent factors affecting OS (Hazard ratio [HR] = 0.39, 2.043 and 0.365, respectively; P = 0.018, 0.001 and 0.032, respectively). The intervention of radiotherapy was an independent factor for PFS (hazard ratio [HR] = 18.149, P = 0.013). The median OS and PFS for patients who had complete response and partial response (Objective response, ORR) were 50.8 months (95% CI 25.8-75.7 months) and 20.5 months (95% CI 14.1-27.0), respectively, which were significantly higher than those in the non-ORR group (OS ICIs combined with radiotherapy/chemotherapy are safe and effective in LA/RM ESCC patients. Intervention of radiotherapy, the number of immunotherapy cycles and occurrence of dysphagia affecting the overall survival of LR/RM ESCC patients. Intervention of radiotherapy was an independent prognosis factor for OS and PFS and associated with better treatment response.
Identifiants
pubmed: 37665394
doi: 10.1007/s12672-023-00783-3
pii: 10.1007/s12672-023-00783-3
pmc: PMC10477157
doi:
Types de publication
Journal Article
Langues
eng
Pagination
165Informations de copyright
© 2023. Springer Science+Business Media, LLC.
Références
Cancers (Basel). 2022 Oct 21;14(20):
pubmed: 36291954
Clin Transl Radiat Oncol. 2022 Nov 02;38:130-137
pubmed: 36425536
JAMA. 2021 Sep 14;326(10):916-925
pubmed: 34519801
Lancet Glob Health. 2018 May;6(5):e555-e567
pubmed: 29653628
J Clin Oncol. 2020 Nov 20;38(33):3863-3873
pubmed: 32910710
Chin Med J (Engl). 2021 Mar 17;134(7):783-791
pubmed: 33734139
Biomed Res Int. 2022 Aug 5;2022:7331687
pubmed: 36033564
Esophagus. 2021 Jan;18(1):90-99
pubmed: 33170461
J Cancer Res Ther. 2022 Apr;18(2):545-552
pubmed: 35645126
Radiother Oncol. 2021 Oct;163:114-118
pubmed: 34419505
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
J Clin Oncol. 2022 Apr 20;40(12):1301-1311
pubmed: 35108059
PLoS One. 2021 May 14;16(5):e0251811
pubmed: 33989365
ESMO Open. 2022 Feb;7(1):100341
pubmed: 34973513
Nature. 2015 Apr 16;520(7547):353-357
pubmed: 25830880
Cell. 2009 Dec 24;139(7):1315-26
pubmed: 20064377
Cancer. 2022 Jun 1;128(11):2148-2158
pubmed: 35319779
Lancet. 2021 Aug 28;398(10302):759-771
pubmed: 34454674
Front Oncol. 2022 Aug 03;12:887525
pubmed: 35992797
Cancers (Basel). 2022 Aug 16;14(16):
pubmed: 36010949
Cancers (Basel). 2021 Jun 17;13(12):
pubmed: 34204314
Cancer Lett. 2019 Jun 28;452:66-70
pubmed: 30902563
Curr Oncol. 2022 Apr 20;29(5):2920-2927
pubmed: 35621628
Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):611-616
pubmed: 35643253
J Thorac Cardiovasc Surg. 2021 Mar;161(3):836-843.e1
pubmed: 33485662
Nature. 2015 Apr 16;520(7547):373-7
pubmed: 25754329
Neoplasia. 2023 Feb;36:100867
pubmed: 36563632
Radiat Oncol. 2019 Oct 22;14(1):181
pubmed: 31640802
JAMA Netw Open. 2022 Nov 1;5(11):e2239778
pubmed: 36322089
J Clin Oncol. 2019 Jun 20;37(18):1558-1565
pubmed: 31067138
Oncoimmunology. 2021 Sep 28;10(1):1971418
pubmed: 34616588
Front Immunol. 2022 Nov 10;13:1039020
pubmed: 36439117
Lancet Oncol. 2020 Jun;21(6):832-842
pubmed: 32416073